Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy

Status Completed

Clinical Trial Summary

This study is intended to build on a growing body of literature showing a blood flow abnormality in patients with Becker muscular dystrophy. The investigators' laboratory recently showed that this blood flow abnormality could be corrected by a single oral dose of the drug Tadalafil (also known as Cialis). The investigators now wish to replicate these exciting results using a common nitric oxide donor (sodium nitrate).

Clinical Trial Description

There are 2 phases to this research project: (1) an initial baseline study to confirm the blood flow abnormality in Becker muscular dystrophy, and (2) a subsequent brief treatment trial. There are also 3 optional study protocols: (A) dose-escalation trial, (B) placebo trial, and (C) increased exercise intensity trial.

The baseline study involves an intake history, physical examination, and phlebotomy for blood chemistries and DNA followed by non-invasive forearm blood flow studies (Near Infrared Spectroscopy, Doppler Ultrasound) before and after a brief bout of handgrip exercise (approximately 3-5 hours to complete). Blood flow studies will be performed with the subject's lower body enclosed in an airtight chamber. Blood flow and oxygen delivery to the forearm muscles will be measured before and during application of lower body negative pressure at rest and during handgrip exercise. Lower body negative pressure simulates the blood flow changes that normally occur when a person sits up after lying down.

The results of the baseline study will determine which patients meet preset eligibility criteria to participate in the medication phase of the study. These criteria include (1) normal kidney and liver function tests and normal BNP levels (the latter to exclude heart failure), and (2) abnormal blood flow responses to handgrip exercise.

Eligible patients will be asked to repeat the above laboratory procedures on a subsequent study day after receiving a single dose of sodium nitrate. Eligible patients will also be offered the option to repeat the above laboratory procedures on three subsequent study visits, where upon: (A) the dose of sodium nitrate is increased, (B) a placebo is ingested, and/or (C) the level of exercise in increased.

The investigators plan to enroll 20 adult men with Becker muscular dystrophy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02147639
Study type	Interventional
Source	Cedars-Sinai Medical Center
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	October 2013
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01168908` - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2
Recruiting	`NCT01484678` - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed	`NCT02847975` - Sodium Nitrate to Improve Blood Flow	Phase 1
Recruiting	`NCT02069756` - The Duchenne Registry
Completed	`NCT04585464` - A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults	Phase 1
Recruiting	`NCT04668716` - Brain Involvement in Dystrophinopathies Part 2
Completed	`NCT03236662` - (-)- Epicatechin Becker Muscular Dystrophy	Phase 2
Completed	`NCT01350154` - Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	Phase 2
Enrolling by invitation	`NCT06066580` - Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy	Phase 2
Not yet recruiting	`NCT06363526` - Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.	N/A
Recruiting	`NCT05409079` - Schulze Muscular Dystrophy Ability Clinical Study	N/A
Completed	`NCT01856868` - Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)	Phase 1/Phase 2
Completed	`NCT01557400` - Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada	Phase 3
Recruiting	`NCT02109692` - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies	N/A
Recruiting	`NCT03057002` - UTSW HP [13-C] Pyruvate Injection in HCM
Recruiting	`NCT04583917` - Brain Involvement in Dystrophinopathies Part 1
Completed	`NCT02207283` - PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy	Phase 4
Withdrawn	`NCT03076814` - Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy	N/A
Completed	`NCT00873782` - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy	Phase 1
Not yet recruiting	`NCT05715957` - Follow-up Study on Female Carriers With DMD Gene Variants

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.